Allergan Inc. must disclose documents it shared with two independent consultants to develop a strategy to prevent the U.S. Food and Drug Administration from allowing other drugmakers to make and sell generic versions of its tear-producing drug, Restasis.

The Ireland-based drugmaker is fighting several cases saying it schemed to extend its monopoly over a cyclosporine emulsion prescribed for dry-eye disease beyond the expiration date of its original Restasis patents. The cases have been consolidated in multidistrict litigation in the U.S....